InterPAD - DETAILS

MIGLITOL, 72432-03-2, Glyset, (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol, Bay-m-1099, Miglitolum, Bay m 1099, Miglitol (Glyset), UNII-0V5436JAQW, Seibule, Bay 1099, Miglitolum [Latin], 0V5436JAQW, DTXSID0023323, HSDB 8022, (2R,3R,4R,5S)-1-(2-Hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol, EINECS 276-661-6, NSC-758702, N-(2-Hydroxyethyl)-1-deoxynojirimycin, CHEMBL1561, CHEBI:6935, DTXCID703323, Diastabol, N-hydroxylethyl-1-deoxynojirimycin, Miglitolum (Latin), NSC 758702, Plumarol, MIGLITOL (MART.), MIGLITOL [MART.], 3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-,(2R,3R,4R,5S)-, 3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-, SMR000466381, CAS-72432-03-2, Glyset (TN), Miglitol [USAN:INN:BAN], BAY1099;BAY-m1099, N-(2-Hydroxyethyl)moranoline, N-hydroxyethyl-1-desoxynojirimycin, NCGC00095127-01, N-hydroxyethyl-1-desoxy-nojirimycin, MFCD00867240, SK-983, baym1099, MIGLITOL [USAN], MIGLITOL [INN], MIGLITOL [JAN], MIGLITOL [MI], MIGLITOL [VANDF], 1,5-Dideoxy-1,5-((2-hydroxyethyl)imino)-D-glucitol, MIGLITOL [WHO-DD], 1,5-Dideoxy-1,5-, SCHEMBL22593, MLS000759514, MLS001424128, MLS006011963, BIDD:GT0732, BAY o1099, MIGLITOL [ORANGE BOOK], cid_441314, GTPL4842, Miglitol (JP17/USAN/INN), IBAQFPQHRJAVAV-ULAWRXDQSA-N, HMS2051D05, HMS3713J07, HY-B0481, Tox21_111436, BDBM50242271, AKOS015969689, N-(b-Hydroxyethyl)-1-deoxynojirimycin, Tox21_111436_1, CCG-100920, DB00491, KS-1242, NC00170, NCGC00270540-02, N-(beta-Hydroxyethyl)-1-deoxynojirimycin, M2302, NS00004693, S2589, C07708, C76308, D00625, EN300-119541, AB00639982-06, AB00639982_08, N-hydroxyethyl-1-desoxynojirimycin (BAY o1099), A837526, Q772735, SR-01000759413, SR-01000759413-4, W-104490, BRD-K44779798-001-06-5, Z1269163651, (2R,3R,4R,5S)-1-ethoxy-2-(hydroxymethyl)piperidine-3,4,5-triol, (4R,5R)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol, 1204250-58-7, 3,4,5-PIPERIDINETRIOL, 1-(2-HYDROXYETHYL)-2-(HYDROXYMETHYL)-, (2R-(2.ALPHA.,3.BETA.,4.ALPHA.,5.BETA.))-, 3,4,5-piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha, 5beta))-

Name	Miglitol
PubChem CID	441314
Molecular Weight	207.22g/mol
Synonyms	MIGLITOL, 72432-03-2, Glyset, (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol, Bay-m-1099, Miglitolum, Bay m 1099, Miglitol (Glyset), UNII-0V5436JAQW, Seibule, Bay 1099, Miglitolum [Latin], 0V5436JAQW, DTXSID0023323, HSDB 8022, (2R,3R,4R,5S)-1-(2-Hydroxyethyl)-2-(hydroxymethyl)-3,4,5-piperidinetriol, EINECS 276-661-6, NSC-758702, N-(2-Hydroxyethyl)-1-deoxynojirimycin, CHEMBL1561, CHEBI:6935, DTXCID703323, Diastabol, N-hydroxylethyl-1-deoxynojirimycin, Miglitolum (Latin), NSC 758702, Plumarol, MIGLITOL (MART.), MIGLITOL [MART.], 3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-,(2R,3R,4R,5S)-, 3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-, SMR000466381, CAS-72432-03-2, Glyset (TN), Miglitol [USAN:INN:BAN], BAY1099;BAY-m1099, N-(2-Hydroxyethyl)moranoline, N-hydroxyethyl-1-desoxynojirimycin, NCGC00095127-01, N-hydroxyethyl-1-desoxy-nojirimycin, MFCD00867240, SK-983, baym1099, MIGLITOL [USAN], MIGLITOL [INN], MIGLITOL [JAN], MIGLITOL [MI], MIGLITOL [VANDF], 1,5-Dideoxy-1,5-((2-hydroxyethyl)imino)-D-glucitol, MIGLITOL [WHO-DD], 1,5-Dideoxy-1,5-, SCHEMBL22593, MLS000759514, MLS001424128, MLS006011963, BIDD:GT0732, BAY o1099, MIGLITOL [ORANGE BOOK], cid_441314, GTPL4842, Miglitol (JP17/USAN/INN), IBAQFPQHRJAVAV-ULAWRXDQSA-N, HMS2051D05, HMS3713J07, HY-B0481, Tox21_111436, BDBM50242271, AKOS015969689, N-(b-Hydroxyethyl)-1-deoxynojirimycin, Tox21_111436_1, CCG-100920, DB00491, KS-1242, NC00170, NCGC00270540-02, N-(beta-Hydroxyethyl)-1-deoxynojirimycin, M2302, NS00004693, S2589, C07708, C76308, D00625, EN300-119541, AB00639982-06, AB00639982_08, N-hydroxyethyl-1-desoxynojirimycin (BAY o1099), A837526, Q772735, SR-01000759413, SR-01000759413-4, W-104490, BRD-K44779798-001-06-5, Z1269163651, (2R,3R,4R,5S)-1-ethoxy-2-(hydroxymethyl)piperidine-3,4,5-triol, (4R,5R)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol, 1204250-58-7, 3,4,5-PIPERIDINETRIOL, 1-(2-HYDROXYETHYL)-2-(HYDROXYMETHYL)-, (2R-(2.ALPHA.,3.BETA.,4.ALPHA.,5.BETA.))-, 3,4,5-piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha, 5beta))-
Drug Type	Small molecule
Formula	C₈H₁₇NO₅
SMILES	C1C(C(C(C(N1CCO)CO)O)O)O
InChI	1S/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1
InChIKey	IBAQFPQHRJAVAV-ULAWRXDQSA-N
CAS Number	72432-03-2
ChEMBL ID	CHEMBL1561
ChEBI ID	CHEBI:6935
TTD ID	D0D0ZD
Drug Bank ID	DB00491
KEGG ID	C07708
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Miglitol
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.